Trastuzumab Emtansine
Breast Inflammatory Carcinoma
Hoffmann-La Rocheantibody_drug_conjugatePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Breast Inflammatory Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
Vinorelbine M.D. Anderson Cancer Center | Phase 2 | B |
Pembrolizumab Northwestern University | Phase 2 | B |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | B |
Sargramostim Academic and Community Cancer Research United | Phase 2 | B |
View all 12 →
Same molecule, other indications
Trastuzumab Emtansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →